Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.81 USD | -0.06% | +2.77% | +26.13% |
Sales 2024 * | 162M 222M | Sales 2025 * | 293M 401M | Capitalization | 1.61B 2.21B |
---|---|---|---|---|---|
Net income 2024 * | -32M -43.74M | Net income 2025 * | 91M 124M | EV / Sales 2024 * | 9.78 x |
Net cash position 2024 * | 27.06M 36.98M | Net cash position 2025 * | 95.46M 130M | EV / Sales 2025 * | 5.18 x |
P/E ratio 2024 * |
-257
x | P/E ratio 2025 * |
7.26
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.1% |
Latest transcript on Avadel Pharmaceuticals plc
1 day | -0.06% | ||
1 week | +2.77% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 17.81 | -0.06% | 452,421 |
24-04-25 | 17.82 | +0.91% | 777,335 |
24-04-24 | 17.66 | -2.38% | 444,065 |
24-04-23 | 18.09 | +4.57% | 985,700 |
24-04-22 | 17.3 | -0.17% | 823,511 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.13% | 1.61B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- AVDL Stock